PUBLISHER: DelveInsight | PRODUCT CODE: 1114689
PUBLISHER: DelveInsight | PRODUCT CODE: 1114689
DelveInsight's, "Lennox-Gastaut Syndrome (LGS) - Pipeline Insight, 2022," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lennox-Gastaut Syndrome (LGS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Lennox-Gastaut Syndrome (LGS) Understanding
Lennox-Gastaut Syndrome (LGS): Overview
Lennox-Gastaut syndrome (LGS) is a severe form of epilepsy that typically becomes apparent during infancy or early childhood. Children with Lennox-Gastaut syndrome may also develop cognitive dysfunction, delays in reaching developmental milestones and behavioral problems. The symptoms of Lennox-Gastaut syndrome usually begin during infancy or childhood, most often between 3 to 5 years of age. Most affected individuals experience multiple types of seizures, multiple times throughout the day. A diagnosis of Lennox-Gastaut syndrome is usually made based upon a thorough clinical evaluation, a detailed patient history and a complete physical and neurological evaluation including advanced imaging techniques, such as electroencephalography (EEG) and magnetic resonance imaging (MRI). The three main forms of treatment of Lennox-Gastaut syndrome are anti-epileptic drugs (AEDs), dietary therapy (typically the ketogenic diet) or device/surgery (VNS therapy or corpus callosotomy). Rarely, resective surgery is an option.
"Lennox-Gastaut Syndrome (LGS) - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lennox-Gastaut Syndrome (LGS) pipeline landscape is provided which includes the disease overview and Lennox-Gastaut Syndrome (LGS) treatment guidelines. The assessment part of the report embraces, in depth Lennox-Gastaut Syndrome (LGS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lennox-Gastaut Syndrome (LGS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Lennox-Gastaut Syndrome (LGS) Emerging Drugs Chapters
This segment of the Lennox-Gastaut Syndrome (LGS) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lennox-Gastaut Syndrome (LGS) Emerging Drugs
Soticlestat is a potent, highly selective, oral, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H). In March 2021, Takeda Pharmaceutical Company and Ovid Therapeutics announced that Takeda has entered into an exclusive agreement under which Takeda secured global rights at closing from Ovid to develop and commercialize the investigational medicine soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic encephalopathies, including Dravet Syndrome and Lennox-Gastaut syndrome (LGS). The drug is in Phase III clinical studies for the treatment of Lennox-Gastaut Syndrome (LGS).
Further product details are provided in the report……..
Lennox-Gastaut Syndrome (LGS): Therapeutic Assessment
This segment of the report provides insights about the different Lennox-Gastaut Syndrome (LGS) drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 10+ key companies which are developing the therapies for Lennox-Gastaut Syndrome (LGS). The companies which have their Lennox-Gastaut Syndrome (LGS) drug candidates in the most advanced stage, i.e. Phase III include, Takeda.
DelveInsight's report covers around 10+ products under different phases of clinical development like
Lennox-Gastaut Syndrome (LGS) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Lennox-Gastaut Syndrome (LGS): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Lennox-Gastaut Syndrome (LGS) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lennox-Gastaut Syndrome (LGS) drugs.
Key Questions
Current Treatment Scenario and Emerging Therapies:
Key Players
Key Products